Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 2026

• Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™
• Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab).

Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.¹ Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to expand treatment options for patients with IBD.^2,3

On October 18, Celltrion will host a symposium titled "Navigating the Treatment Journey with Subcutaneous Infliximab Across Clinical Scenarios," Chaired by Professor Peter M. Irving of King's College London, UK, a leading IBD expert.

Celltrion will also host two MTE sessions at its booth. In the first session, Professor Irina Blumenstein of University Hospital Frankfurt, Germany, will share clinical evidence and treatment considerations relating to Remsima™ SC monotherapy, drawing on real-world data and clinical experience.

"UEG Week 2026 provides an opportunity to share clinical evidence and real-world experience with healthcare professionals, underscoring Remsima™ SC’s role in addressing different IBD treatment needs," said Taehun Ha, Senior Vice President and Head of Europe at Celltrion. "We will continue to strengthen our position in the IBD market as a trusted partner for healthcare professionals worldwide."

Notes to Editors:

About Remsima™ SC (CT-P13 SC, subcutaneous infliximab)

CT-P13 SC is the world’s first subcutaneous formulation of infliximab. A fixed dose of 120mg of CT-P13 SC has been approved for use in 60 countries, including the US, UK, EU, Canada, Brazil, Australia and Taiwan, in adults regardless of body weight. The SC formulation of infliximab has the potential to enhance treatment options by providing high consistency in drug exposure and a convenient method of administration.^4,5

About Celltrion

Celltrion is a leading biopharmaceutical company that specializes in researching, developing, manufacturing, marketing, and sales of innovative therapeutics that improve people's lives worldwide. As a biosimilar pioneer, Celltrion launched the world's first monoclonal antibody biosimilar. Its global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology, and endocrinology. Beyond biosimilar products, Celltrion advances novel drug pipelines to push the boundaries of scientific innovation and deliver quality medicines. For more information, visit www.celltrion.com/en-us or follow on LinkedIn, Instagram, X, and Facebook.

FORWARD-LOOKING STATEMENT

Certain information outlined in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws. This press release contains forward-looking statements. These statements may also be identified by words such as "prepares", "hopes to", "upcoming", "plans to", "aims to", "to be launched", "is preparing", "once gained", "could", "with the aim of", "may", "once identified", "will", "working towards", "is due", "become available", "has potential to", “anticipates”, the negative of these words or such other variations thereon or comparable terminology.

In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion Inc. and its subsidiaries' management, of which many are beyond its control.

Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.

Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements.

Celltrion Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws.

References

^1European Medicines Agency Summary of Product Characteristics (SmPC), Remsima. Available at link to SmPC [Last accessed October 2026].

^2European Medicines Agency Summary of Product Characteristics (SmPC), SteQeyma. Available at link to SmPC [Last accessed October 2026].

^3European Medicines Agency Summary of Product Characteristics (SmPC), Yuflyma. Available at link to SmPC [Last accessed October 2026].

^4Schreiber S et al., Gastroenterology. 2021;160(7):2340-2353

^5Westhovens R et al., Rheumatology. 2021;60(5):2277-2287